Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Last updated: April 25, 2025
Sponsor: Tanta University
Overall Status: Completed

Phase

3

Condition

Primary Biliary Cholangitis

Liver Disease

Treatment

Pentoxifylline

N-acetylcysteine

Clinical Study ID

NCT06236165
00543/2024
  • Ages 18-70
  • All Genders

Study Summary

Investigating the efficacy, safety, and molecular mechanism of N-acetylcysteine supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients age 18-70 years old.

  • Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.

Exclusion

Exclusion Criteria:

  • Pregnancy.

  • Nursing mothers.

  • Patients with increased indirect bilirubin level.

  • Patients who have Gilbert syndrome or Crigler Najjar syndrome.

  • Patients with Child Paugh C score (10-15 point).

  • History of known hypersensitivity to N-acetylcysteine.

Study Design

Total Participants: 44
Treatment Group(s): 2
Primary Treatment: Pentoxifylline
Phase: 3
Study Start date:
February 14, 2024
Estimated Completion Date:
January 22, 2025

Connect with a study center

  • Faculty of Pharmacy, Tanta University

    Tanta, 31111
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.